Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19
Coronavirus disease-2019 (COVID-19) pandemic has become a global threat and death tolls are increasing worldwide. The SARS-CoV-2 though shares similarities with SARS-CoV and MERS-CoV, immunopathology of the novel virus is not understood properly. Previous reports from SARS and MERS-CoV documents tha...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1796425 |
| _version_ | 1797677296874684416 |
|---|---|
| author | Kumaragurubaran Karthik Tuticorin Maragatham Alagesan Senthilkumar Shanmugasundaram Udhayavel Gopal Dhinakar Raj |
| author_facet | Kumaragurubaran Karthik Tuticorin Maragatham Alagesan Senthilkumar Shanmugasundaram Udhayavel Gopal Dhinakar Raj |
| author_sort | Kumaragurubaran Karthik |
| collection | DOAJ |
| description | Coronavirus disease-2019 (COVID-19) pandemic has become a global threat and death tolls are increasing worldwide. The SARS-CoV-2 though shares similarities with SARS-CoV and MERS-CoV, immunopathology of the novel virus is not understood properly. Previous reports from SARS and MERS-CoV documents that preexisting, non-neutralizing or poorly neutralizing antibodies developed as a result of vaccine or infection enhance subsequent infection, a phenomenon called as antibody-dependent enhancement (ADE). Since immunotherapy has been implicated for COVID-19 treatment and vaccine is under development, due consideration has to be provided on ADE to prevent untoward reactions. ADE mitigation strategies like the development of vaccine or immunotherapeutics targeting receptor binding motif can be designed to minimize ADE of SARS-CoV-2 since full-length protein-based approach can lead to ADE as reported in MERS-CoV. The present mini-review aims to address the phenomenon of ADE of SARS-CoV-2 through the lessons learned from SARS-CoV and MERS-CoV and ways to mitigate them so as to develop better vaccines and immunotherapeutics against SARS-CoV-2. |
| first_indexed | 2024-03-11T22:42:42Z |
| format | Article |
| id | doaj.art-adac1765b0fd4292b03e065b10bd8e67 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:42:42Z |
| publishDate | 2020-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-adac1765b0fd4292b03e065b10bd8e672023-09-22T08:51:50ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2020-12-0116123055306010.1080/21645515.2020.17964251796425Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19Kumaragurubaran Karthik0Tuticorin Maragatham Alagesan Senthilkumar1Shanmugasundaram Udhayavel2Gopal Dhinakar Raj3Tamil Nadu Veterinary and Animal Sciences UniversityTamil Nadu Veterinary and Animal Sciences UniversityTamil Nadu Veterinary and Animal Sciences UniversityTamil Nadu Veterinary and Animal Sciences UniversityCoronavirus disease-2019 (COVID-19) pandemic has become a global threat and death tolls are increasing worldwide. The SARS-CoV-2 though shares similarities with SARS-CoV and MERS-CoV, immunopathology of the novel virus is not understood properly. Previous reports from SARS and MERS-CoV documents that preexisting, non-neutralizing or poorly neutralizing antibodies developed as a result of vaccine or infection enhance subsequent infection, a phenomenon called as antibody-dependent enhancement (ADE). Since immunotherapy has been implicated for COVID-19 treatment and vaccine is under development, due consideration has to be provided on ADE to prevent untoward reactions. ADE mitigation strategies like the development of vaccine or immunotherapeutics targeting receptor binding motif can be designed to minimize ADE of SARS-CoV-2 since full-length protein-based approach can lead to ADE as reported in MERS-CoV. The present mini-review aims to address the phenomenon of ADE of SARS-CoV-2 through the lessons learned from SARS-CoV and MERS-CoV and ways to mitigate them so as to develop better vaccines and immunotherapeutics against SARS-CoV-2.http://dx.doi.org/10.1080/21645515.2020.1796425covid-19sars-cov-2antibody-dependent enhancementvaccineimmunotherapymabsspike protein |
| spellingShingle | Kumaragurubaran Karthik Tuticorin Maragatham Alagesan Senthilkumar Shanmugasundaram Udhayavel Gopal Dhinakar Raj Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19 Human Vaccines & Immunotherapeutics covid-19 sars-cov-2 antibody-dependent enhancement vaccine immunotherapy mabs spike protein |
| title | Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19 |
| title_full | Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19 |
| title_fullStr | Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19 |
| title_full_unstemmed | Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19 |
| title_short | Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19 |
| title_sort | role of antibody dependent enhancement ade in the virulence of sars cov 2 and its mitigation strategies for the development of vaccines and immunotherapies to counter covid 19 |
| topic | covid-19 sars-cov-2 antibody-dependent enhancement vaccine immunotherapy mabs spike protein |
| url | http://dx.doi.org/10.1080/21645515.2020.1796425 |
| work_keys_str_mv | AT kumaragurubarankarthik roleofantibodydependentenhancementadeinthevirulenceofsarscov2anditsmitigationstrategiesforthedevelopmentofvaccinesandimmunotherapiestocountercovid19 AT tuticorinmaragathamalagesansenthilkumar roleofantibodydependentenhancementadeinthevirulenceofsarscov2anditsmitigationstrategiesforthedevelopmentofvaccinesandimmunotherapiestocountercovid19 AT shanmugasundaramudhayavel roleofantibodydependentenhancementadeinthevirulenceofsarscov2anditsmitigationstrategiesforthedevelopmentofvaccinesandimmunotherapiestocountercovid19 AT gopaldhinakarraj roleofantibodydependentenhancementadeinthevirulenceofsarscov2anditsmitigationstrategiesforthedevelopmentofvaccinesandimmunotherapiestocountercovid19 |